Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunic gets a "positive surprise" from lead asset trial By: News Direct April 13, 2023 at 08:00 AM EDT --News Direct--Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).Vitt describes it as "wonderful data" that came as a "positive surprise."Contact DetailsProactive United StatesProactive United States+1 347-449-0879action@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718 Related Stocks: Immunic Inc Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Immunic gets a "positive surprise" from lead asset trial By: News Direct April 13, 2023 at 08:00 AM EDT --News Direct--Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).Vitt describes it as "wonderful data" that came as a "positive surprise."Contact DetailsProactive United StatesProactive United States+1 347-449-0879action@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718 Related Stocks: Immunic Inc